VA106483 Dose Response in Females

Nocturia Clinical Trial

Official title:

An Open Label, Dose Escalation Study to Assess Intra-Subject Dose Response to VA106483 in Female Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01171391
• Other study ID #: 483-007
• Status: Completed
• Phase: Phase 1
• First received: July 19, 2010
• Last updated: November 30, 2010
• Start date: July 2010
• Est. completion date: November 2010

Study information

• Verified date: November 2010
• Source: Vantia Ltd
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to describe the pharmacokinetics and pharmacodynamics of VA106483 in female subjects.

Description:

Nocturia, defined as waking to void at least once per night between periods of sleep, is a common complaint and shows an age-dependent increase in both prevalence and severity (number of nocturnal voids). The most common causes are detrusor over-activity, reduced nighttime functional bladder capacity, and nocturnal polyuria.

VA106483 is a selective vasopressin V2-receptor agonist in development for nocturia. VA106483 is a non-peptide drug that displays much improved oral availability over desmopressin and low dependence on glomerular filtration for its elimination.

VA106483 has been administered to 184 subjects (including healthy adult subjects [males and females], children [males and females] with nocturia and 48 elderly males [aged 65 years and over]). It has been administered as single doses both intravenously, up to doses of approximately 250 mg and orally up to 50 mg It is also being investigated in approximately 123 male subjects (two-thirds on active medication, one third on placebo) with nocturia in a current study with dosing for up to 8 weeks.

This intra-subject dose escalation study has previously been conducted in 10 elderly male subjects to determine whether subjects demonstrated a dose-dependent pharmacokinetic and pharmacodynamic (urine osmolality and diuresis) response and whether the dose of VA106483 could be titrated within an individual patient to achieve optimal clinical response in clinical practice. Given that to date, only 8 females have been exposed to VA106483, the purpose of this study is to confirm that the described duration of pharmacokinetics and pharmacodynamics of VA106483 in males is similar in females.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Female subjects 40 years and above

• BMI 18 to 32 kg/m2

• Using adequate contraception and providing negative pregnancy tests pre-dose

• In good health as determined by medical history and screening tests

• Subject is willing and able to abstain from alcohol and caffeine-containing food and beverages 72 hours prior to dosing and throughout the study

• Provide written, informed consent

Exclusion Criteria:

• Pregnancy or lactation

• Evidence of serious pathology or diseases including heart, hormone, liver and kidney, psychiatric and neurological problems, including syndrome of inappropriate antidiuretic hormone secretion, polydipsia or diabetes insipidus

• Likely to be hypersensitive to VA106483

• History of any relevant allergy

• Participation in a clinical study within 30 days

• Donation of blood (500 mL) within 60 days prior to dosing

• A history of alcohol abuse or drug addiction

• Positive results for HIV, HBV or HCV or drugs of abuse

• Currently taking any diuretics or clinically significant cytochrome 3A4 inhibitors or inducers

• Use of any non-prescription preparation within 72 hours prior to dosing, with the exception of ibuprofen, and acetaminophen used at recommended doses

• Treatment within the previous 3 months of drugs known to have a well defined potential for hepatoxicity

• Current smokers or recent ex-smokers

• Other protocol defined eligibility criteria may apply

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Nocturia

Intervention

Drug:
• VA106483
1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7

Other:
• Placebo
Placebo on Day 1

Locations

Country	Name	City	State
United States	Quintiles Phase I Services	Overland Park	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Vantia Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics	VA106483 plasma concentration pre-dose over a 24hr post-dose period to assess pharmacokinetics of each dose level	10 days	No
Secondary	Pharmacodynamics	Urine volume and osmolality	10 days	No
Secondary	Safety and Tolerability	AEs, laboratory safety tests, vital signs and ECG, physical examination.	10 days	Yes